- Sanofi is going to produce Johnson & Johnson’s COVID-19 vaccine in France.
- At its manufacturing plant, Sanofi will fill vials of COVID-19 vaccine.
- Plan is to produce 12 million doses per month.
French drug maker Sanofi is going to provide support in manufacturing the COVID-19 vaccine that has been developed by American company Johnson & Johnson. The two rivals appear to be setting their differences aside in order to help address global supply demands.
Sanofi announced its partnership with Janssen pharmaceuticals, Inc and Janssen pharmaceutical NV in a statement. Johnson & Johnson is the parent company of these two companies. Sanofi is waiting for approval from the American authorities and European authorities to produce as well as market the COVID-19 vaccine. According to the statement, once authorized, Sanofi will provide Johnson & Johnson access to its vaccine manufacturing plant in Lyon city to formulate as well as fill vials of Janssen’s vaccine candidate. The plan is to produce approximately 12 million doses per month.
This is the second time for Sanofi forming a partnership with a rival as its own vaccine candidate is facing delays. In JAN 2021, the French drug maker entered a similar agreement to provide manufacturing support to the vaccine that was being jointly produced by BioNTech and Pfizer.
Sanofi has resumed also resumed the Phase 2 trial on its own COVID-19 vaccine which it is manufacturing with UK’s GSK. The new study will be evaluating the immunogenicity, reactogenicity, and safety of the vaccine in 720 volunteers aged 18-59. Based on the results, the company is hoping to start Phase 3 trial. Sanofi hopes to make its vaccine available by the end of 2021.